Global Encapsulated Live Cell Market Growth (Status and Outlook) 2023-2029

Global Encapsulated Live Cell Market Growth (Status and Outlook) 2023-2029

Live cell encapsulation has long been proposed as a solution in modern medicine to many therapeutic problems. Cell encapsulation technology is used for the immobilization of cells within biocompatible and semipermeable membranes. The encapsulation of cells, instead of therapeutic products, is used to allow the delivery of molecules of interest for a longer time period as cells release these molecules of interest continuously. Furthermore, cells can be engineered for expressing the protein of interest in vivo without modifying the host’s genome. Cell encapsulation presents a significant advantage compared to protein encapsulation, as cell encapsulation allows a sustained and controlled delivery therapeutic molecules at a constant rate, thereby resulting in greater physiological concentrations.

LPI (LP Information)' newest research report, the “Encapsulated Live Cell Industry Forecast” looks at past sales and reviews total world Encapsulated Live Cell sales in 2022, providing a comprehensive analysis by region and market sector of projected Encapsulated Live Cell sales for 2023 through 2029. With Encapsulated Live Cell sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Encapsulated Live Cell industry.

This Insight Report provides a comprehensive analysis of the global Encapsulated Live Cell landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Encapsulated Live Cell portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Encapsulated Live Cell market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Encapsulated Live Cell and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Encapsulated Live Cell.

The global Encapsulated Live Cell market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Encapsulated Live Cell is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Encapsulated Live Cell is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Encapsulated Live Cell is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Encapsulated Live Cell players cover Viacyte, Inc., Living Cell Technologies Ltd., Sigilon Therapeutics, Inc, Sernova Corporation, PharmaCyte Biotech Inc, Gloriana Therapeutics, Kadimastem, Beta-O2 Technologies, Inc. and Altucell, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Encapsulated Live Cell market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Alginate
Chitosan
Cellulose
Others

Segmentation by application
Diabetes
Cancer
Epilepsy
Parkinson
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Viacyte, Inc.
Living Cell Technologies Ltd.
Sigilon Therapeutics, Inc
Sernova Corporation
PharmaCyte Biotech Inc
Gloriana Therapeutics
Kadimastem
Beta-O2 Technologies, Inc.
Altucell, Inc.
Diatranz Otsuka Ltd

Please note: The report will take approximately 2 business days to prepare and deliver.